GlobeNewswire Inc | Jul 20, 2021 02:00AM EDT

July 20, 2021

-- RYEQO is the first and only once-daily long-term treatment for uterine fibroids in Europe -- Indication has no limitation for duration of use, as supported by safety and efficacy data from the Phase 3 LIBERTY program -- Gedeon Richterto commercialize RYEQO, starting in the second half of 2021; Myovant to receive a regulatory milestone payment and is eligible to receive tiered royalties on net sales as well as sales milestone payments -- Marketing authorization application for RYEQO for endometriosis-associated pain on track for submission this calendar year

BASEL, Switzerland, July 20, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men,today announced the European Commission (EC) has approved the marketing authorization application for RYEQO(relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age, with no limitation for duration of use. The EC decision is valid in all 27 member states of the European Union, as well as Iceland, Norway, and Liechtenstein.

Data from the Phase 3 LIBERTY program, which supported the approval of RYEQO, showed that RYEQO improved symptoms most relevant to women living with uterine fibroids, namely heavy menstrual bleeding and pain, while maintaining a well-tolerated safety profile, saidRoberta Venturella, M.D., Ph.D.,Associate Professor, Magna Grcia University of Catanzaro and investigator in the LIBERTY program. With this approval, women and doctors finally have a long-term treatment option, which is important for the management of this condition.

Todays approval of RYEQO, the first and only once-daily long-term treatment for women with uterine fibroids in Europe, marks a major milestone in expanding non-invasive treatment options for this common and potentially debilitating disease, said David Marek, Chief Executive Officer of Myovant Sciences, Inc. Through our partnership with Gedeon Richter, we look forward to supporting even more women suffering from uterine fibroids.

The approval is based on safety and efficacy data from the Phase 3 LIBERTY program, which consisted of two replicate, 24-week, multinational clinical studies (LIBERTY 1 and LIBERTY 2), a one-year extension study, and supportive bone mineral density data from a randomized withdrawal study. Results from the LIBERTY 1 and LIBERTY 2 studies were published in theNew England Journal of Medicinein February 2021.

In March 2020, Myovant andGedeon Richter entered into an exclusive license agreement forGedeon Richterto commercialize relugolix combination tablet for uterine fibroids and endometriosis inEurope, the Commonwealth of Independent States includingRussia,Latin America,Australia, and New Zealand. Under the agreement, Myovant received an upfront payment of $40 million and is eligible to receive up to $40 million in regulatory milestones and $107.5 million in sales milestones for a total of $147.5 million, and tiered royalties on net sales following regulatory approval. Gedeon Richter will be responsible for local clinical development, manufacturing, and all commercialization for its territories. Myovant and Gedeon Richter will also continue to collaborate on the marketing authorization application for endometriosis, which is expected to be submitted in the second half of calendar year 2021.

About Uterine FibroidsUterine fibroids are noncancerous tumors that develop in or on the muscular walls of the uterus and are among the most common reproductive tract tumors in women. In addition to an individual's genetic predisposition, estrogens are well known to play an important role in the regulation of fibroid growth.

Although uterine fibroids are benign tumors, they can cause debilitating symptoms such as heavy menstrual bleeding (frequently resulting in anemia and fatigue), pain (including painful periods, abdominal pain, painful intercourse, backache), increased abdominal girth and bloating, urinary frequency or retention, constipation, pregnancy loss, and, in some cases, infertility. These symptoms can also lead to loss of productivity at work, limitations in normal activities of daily living, and social embarrassment.

About RYEQORYEQO (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. RYEQO contains relugolix, which reduces the amount of estrogen (and other hormones) produced by ovaries, estradiol (an estrogen), which may reduce the risk of bone loss, and norethindrone acetate (a progestin), which is necessary when women with a uterus (womb) take estrogen.

AboutMyovant SciencesMyovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, we have two FDA-approved products. ORGOVYX (relugolix) was approved by the U.S. Food and Drug Administration in 2020 as the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and relugolix is also under regulatory review in Europe for men with advanced prostate cancer.Relugolix combination tablet (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) was approved in 2021 in the EU as RYEQOfor the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age, and in the U.S. as MYFEMBREE as the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. The therapy has also completed Phase 3 registration-enabling studies for women with endometriosis, and is being assessed for contraceptive efficacy in healthy women ages 18-35 years who are at risk for pregnancy. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website atwww.myovant.com. Follow@Myovanton Twitter andLinkedIn.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this press release, forward-looking statements include, but are not limited to, all statements reflecting Myovant Sciences expectations, including: statements regarding Myovants aspiration to redefine care for women and for men; the expectations of commercialization of RYEQOfor uterine fibroids inEuropebyGedeon Richter; the submission of the marketing authorization application for RYEQO for endometriosis-associated pain; Myovants expectations regarding the potential benefits of RYEQOand it serving as a long-term treatment option for managing heavy menstrual bleeding and pain associated with uterine fibroids; and Myovants expectations regarding Myovant and Gedeon Richters responsibilities and continued efforts to collaborate on the marketing authorization application for endometriosis.

Myovant Sciences forward-looking statements are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties, assumptions and other factors known and unknown that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements, including unforeseen circumstances or other disruptions to normal business operations arising from or related to the COVID-19 pandemic.Myovant Sciencescannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could materially affect Myovant Sciences operations and future prospects or which could cause actual results to differ materially from expectations include, but are not limited to the risks and uncertainties listed in Myovant Sciences filings with theUnited States Securities and Exchange Commission(SEC), including under the heading Risk Factors in Myovant Sciences Annual Report on Form 10-K filed onMay 11, 2021, as such risk factors may be amended, supplemented or superseded from time to time. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for Myovant Sciences management to predict all risk factors, nor canMyovant Sciencesassess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof, and, except as required by law,Myovant Sciencesundertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements.

Investor Contact:Ryan CroweVice President, Investor RelationsMyovant Sciences, Inc.+1 (650) 781-9106investors@myovant.com

Media Contact:Albert LiaoDirector, Corporate CommunicationsMyovant Sciences, Inc.+1 (650) 410-3055media@myovant.com